Everything below concerns Prohibited substance. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
The majority of serpin diseases are due to protein aggregation and are termed "serpinopathies". Serpins are vulnerable to disease-causing mutations that promote formation of misfolded polymers due to their inherently unstable structures. Well-characterised serpinopathies include α1-antitrypsin deficiency (alpha-1), which may cause familial emphysema, and sometimes liver cirrhosis, certain familial forms of thrombosis related to antithrombin deficiency, types 1 and 2 hereditary angioedema (HAE) related to deficiency of C1-inhibitor, and familial encephalopathy with neuroserpin inclusion bodies (FENIB; a rare type of dementia caused by neuroserpin polymerisation). Each monomer of the serpin aggregate exists in the inactive, relaxed conformation (with the RCL inserted into the A-sheet). The polymers are therefore hyperstable to temperature and unable to inhibit proteases. Serpinopathies therefore cause pathologies similarly to other proteopathies (e.g. prion diseases) via two main mechanisms. First, the lack of active serpin results in uncontrolled protease activity and tissue destruction. Second, the hyperstable polymers themselves clog up the endoplasmic reticulum of cells that synthesize serpins, eventually resulting in cell death and tissue damage. In the case of antitrypsin deficiency, antitrypsin polymers cause the death of liver cells, sometimes resulting in liver damage and cirrhosis. Within the cell, serpin polymers are slowly removed via degradation in the endoplasmic reticulum.
=== Analogues === Analogues of 6-HO-DET include diethyltryptamine (DET), 6-hydroxytryptamine (6-HT or 6-HO-T), 6-HO-DMT, 6-MeO-DMT, 6-methyl-DMT, 6-fluoro-DET, psilocin (4-HO-DMT), 4-HO-DET, bufotenin (5-HO-DMT), 7-HO-DMT, 5-HO-DET, 5-HO-DPT, and 5-HO-DiPT, among others.
== Interactions == The hypotensive effects of butizide can be increased by antihypertensive drugs (especially ACE inhibitors), barbiturates, tricyclic antidepressants, and ethanol. Combination with beta blockers can increase blood glucose levels; and conversely, butizide can decrease the effects of antidiabetic drugs. As butizide lowers blood potassium and magnesium levels, it can increase the effects of cardiac glycosides. It can also increase lithium toxicity. Nonsteroidal anti-inflammatory drugs can decrease the diuretic effect of butizide.
Sources: en.wikipedia.org
China conducted a state-sanctioned doping programme on athletes in the 1980s and 1990s. The majority of revelations of Chinese doping have focused on swimmers and track and field athletes, such as Ma Junren's Ma Family Army (馬家軍). More recently, three Chinese weightlifters were stripped of their gold Olympic medals for doping at the 2008 Summer Olympics. In a July 2012 interview published by the Sydney Morning Herald newspaper, Chen Zhangho, the lead doctor for the Chinese Olympic team at the Los Angeles, Seoul and Barcelona Olympics told of how he had tested hormones, blood doping and steroids on about fifty elite athletes. Chen also accused the United States, the Soviet Union and France of using performance-enhancing drugs at the same time as China. In 2012 and 2017 Xue Yinxian revealed systematic doping of Chinese athletes in Olympic Games (and in other international sport events). He has claimed that more than 10,000 athletes in China were doped in the systematic Chinese government doping program and that they received performance-enhancing drugs in the 1980s and 1990s. He stated that the entirety of international medals (both in the Olympics and other international competitions) won by Chinese athletes in the 1980s and 1990s must be taken back. This is contrary to previous statements by the Chinese government, which had denied involvement in systematic doping, claiming that athletes doped individually. The International Olympic Committee and the World Anti-Doping Agency have investigated these allegations.
=== Alleviation of dysphoria theory === The alleviation of dysphoria theory suggests that people with severe mental illness commonly have a negative self-image, which makes them vulnerable to using psychoactive substances to alleviate these feelings. Despite the existence of a wide range of dysphoric feelings (anxiety, depression, boredom, and loneliness), the literature on self-reported reasons for use seems to lend support for the experience of these feelings being the primary motivator for alcohol use disorder and other drug misuse.
== Origin == The Kalyāṇakāraka, composed in South India by Ugrāditya, is the earliest medical work to contain alchemical content. It is datable to the early ninth century CE. It gives descriptions for the processing of mercury and uses technical terminology related to the procedures and implements required for alchemy. It is the first work to describe purifying (śodhana) and calcining (māraṇaʼ) mercury for medicinal use. The first work of the Sanskrit alchemical literary genre called rasaśāstra is the 10th century Rasahṛdayatantra. The texts 19 chapters focus on the processing mercury, outlines 18 means to process mercury and discusses the transmutation of metals and the body.
Sources: en.wikipedia.org
== Early life and education == Born in 1953 and raised in Dearborn, Michigan, Tippett is an alumnus of Kalamazoo College and holds a Ph.D. and M.D. from Case Western Reserve University School of Medicine. He studied at the Rockefeller University in New York under Nobel Prize winner Robert Bruce Merrifield, directing his doctoral research efforts toward the metabolic indicators of peptide synthesis. He completed his internship and residency in Internal Medicine at Cleveland Metropolitan General Hospital, and spent 1975-1985 engaged in biochemical research.
During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Trinoid #0 Saunaginnan resurrects Ben G, who is subsequently killed by Deka Master, Pink, and Break, as well as Abare Killer. Ben G is voiced by Nobuyuki Hiyama (檜山 修之, Hiyama Nobuyuki). Cristonian Ferley (クリスト星人ファーリー, Kurisuto Seijin Fārī): A werewolf/vampire bat–themed criminal from Planet Cristo who is charged with burglary and murdering several S.P.D. officers. As his body is photosensitive, he tasks a Batsuroid with piloting a Kaijuki called Devil Capture 4 (デビルキャプチャー4, Debiru Kyapuchā Fō) to distract the Dekarangers while Ferley locates and eats a mineral called Lunar Metal so he can roam freely in daylight. Devil Capture 4 is destroyed by Dekaranger Robo while Ferley is deleted by the Dekarangers via the D-Bazooka. In the direct-to-video special Tokusou Sentai Dekaranger Super Video: Super Finisher Match! Deka Red vs. Deka Break, a variation of Ferley called Burning Ferley (バーニング・ファーリー, Bāningu Fārī) appears as part of a simulation training session. Ferley is voiced by Hisao Egawa (江川 央生, Egawa Hisao). Titarnian Metiussl (ティタン星人メテウス, Titan Seijin Meteusu): A brutal flame/astronaut–themed criminal and self-proclaimed "Destroyer King" (破壊王, Hakaiō) from Planet Titarn who seeks out an android girl named Flora, whom he created to control his giant creation Machine Monster Gigas (マシンモンスター・ギーガス, Mashin Monsutā Gīgasu). He tasks a Batsuroid with piloting a gladiator-themed Kaijuki called Cannon Gladiator (キャノングラディエーター, Kyanon Guradiētā) and attacking the Deka Base while he locates Flora.
=== Peru === The travelers gradually descended into the cinchona forests and former Inca territories. In Riobamba, they stayed with Montufar’s brother, where Humboldt accessed rare sixteenth-century manuscripts written in an extinct dialect and later translated into Spanish. These documents described pre-conquest events and the major eruption of Nevado de Altar volcano, which affected nearby towns with ash for seven years. Traveling from Riobamba to Cuenca across the Paramo of Azuay, Humboldt studied the remains of the Inca road, notable for its precise porphyry paving and straightness, comparable to Roman roads, leading to Cuzco. He also visited the ruins of Inca Tapayupangi’s palace and its summer house carved from rock, which offered impressive views and prompted Humboldt to admire Inca public works. Southward, the group had to ford the Rio Guancabamba, a tributary of the Amazon, twenty-seven times. Although not wide, the river’s strong current endangered their mules, which carried important collections. Humboldt described the anxiety of watching their passage. Further along, he observed the local postal system known as “el correo que nada,” where a messenger swam downstream with mail secured in a cotton handkerchief, sometimes using a balsa log to rest and stopping at huts for food and shelter. Humboldt confirmed the reliability of this system, having received mail sent this way in Paris, and noted that groups of people also traveled the river in this manner.
The upper gastrointestinal tract consists of the mouth, pharynx, esophagus, stomach, and duodenum. The exact demarcation between the upper and lower tracts is the suspensory muscle of the duodenum. This differentiates the embryonic borders between the foregut and midgut, and is also the division commonly used by clinicians to describe gastrointestinal bleeding as being of either "upper" or "lower" origin. Upon dissection, the duodenum may appear to be a unified organ, but it is divided into four segments based on function, location, and internal anatomy. The four segments of the duodenum are as follows (starting at the stomach, and moving toward the jejunum): bulb, descending, horizontal, and ascending. The suspensory muscle of the duodenum suspends the superior border of the ascending duodenum from the diaphragm, and serves as an important anatomical landmark showing the formal division between the duodenum and the jejunum, the first and second parts of the small intestine, respectively. This is a thin muscle which is derived from the embryonic mesoderm.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.